Page last updated: 2024-10-17

creatine and Menopause

creatine has been researched along with Menopause in 8 studies

Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.

Research Excerpts

ExcerptRelevanceReference
" It is likely that a higher dosage would be more effective, but would cause the potential endometrial effects."2.65Bone loss during oestriol therapy in postmenopausal women. ( Clark, AC; Garwood, J; Hart, DM; Kraszewski, A; Lindsay, R; Maclean, A, 1979)
"We conducted a dose-response study in 23 postmenopausal women to compare the physiologic effects of transdermal estradiol and oral conjugated equine estrogens."1.27Biologic effects of transdermal estradiol. ( Alkjaersig, NK; Chetkowski, RJ; Eggena, P; Fletcher, AP; Hershman, JM; Judd, HL; Lu, JK; Meldrum, DR; Randle, D; Steingold, KA, 1986)
"In patients with breast and prostate cancer hormone excretion patterns differ in a similar way from patterns in persons without cancer."1.24HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL. ( HOPKINS, CE; MARMORSTON, J; STERN, E; WEINER, JM, 1964)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19905 (62.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Smith-Ryan, AE1
Cabre, HE1
Eckerson, JM1
Candow, DG1
Liu, X1
Wang, L1
Peng, D1
Wang, Y1
Ren, M1
YAHIA, C1
TAYMOR, ML1
BUYTENDORP, A1
SORENSEN, AW1
STERN, E1
HOPKINS, CE1
WEINER, JM1
MARMORSTON, J1
Lindsay, R1
Hart, DM1
Maclean, A1
Garwood, J1
Clark, AC1
Kraszewski, A1
Packer, E1
Holloway, L1
Newhall, K1
Kanwar, G1
Butterfield, G1
Marcus, R1
Chetkowski, RJ1
Meldrum, DR1
Steingold, KA1
Randle, D1
Lu, JK1
Eggena, P1
Hershman, JM1
Alkjaersig, NK1
Fletcher, AP1
Judd, HL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model[NCT04051320]Phase 223 participants (Actual)Interventional2020-01-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Correlation Between Irritability and Reactive Aggression During Hormone Addback

"This outcome measure determines the degree of irritability and reactive aggression in HS+ during hormone addback and its relationship to the target population. Irritability will be defined as score on the IDAS Ill Temper Scale. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~The Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to ac" (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)0.18
Hormone Insensitive Women (HS-)0.03

Correlation Between Irritability Subcortical Activation in HS+ During Hormone Addback

"This outcome measure determines the degree of subcortical (amygdala, caudate, putamen, and nucleus accumbens) activation in HS+ during hormone addback and it's relationship to the target population. The activation in amygdala and ventral striatum (caudate, putamen, nucleus accumbens) regions of interest (ROIs) will be assessed during the Affective Posner Task.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)0.47

Correlation Between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill -0.8Scale and Threat Attention Bias

This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper (i.e., irritability) Scale and threat attention bias. (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)-0.35
Hormone Insensitive Women (HS-)0.11

Correlation Between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper Scale and Left Amygdala-medial Prefrontal Cortex (PFC) BOLD Connectivity.

This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Mean)
Hormone Sensitive Women (HS+)-0.13
Hormone Insensitive Women (HS-)0.49

Correlation Between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper Scale and Right Amygdala-medial Prefrontal Cortex (PFC) BOLD Connectivity.

This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)-0.57
Hormone Insensitive Women (HS-)-0.08

Mean BOLD Activation of the Left Amygdala During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)-0.009866667-0.086876444
Hormone Sensitive Women (HS+)0.005316917-0.047401917

Mean BOLD Activation of the Left Caudate During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0077258-0.049988
Hormone Sensitive Women (HS+)-0.0439433330.059099917

Mean BOLD Activation of the Left Nucleus Accumbens During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0691907-0.072512
Hormone Sensitive Women (HS+)-0.0284518180.031632727

Mean BOLD Activation of the Left Putamen During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0383029-0.021029
Hormone Sensitive Women (HS+)-0.0012234620.048155385

Mean BOLD Activation of the Right Amygdala During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.037334-0.15643
Hormone Sensitive Women (HS+)-0.045440.022654

Mean BOLD Activation of the Right Caudate During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0614070.0058011
Hormone Sensitive Women (HS+)-0.0699190770.045146154

Mean BOLD Activation of the Right Nucleus Accumbens During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.052685333-0.006394444
Hormone Sensitive Women (HS+)0.044384167-0.005181667

Mean BOLD Activation of the Right Putamen During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.002542222-0.080736333
Hormone Sensitive Women (HS+)-0.0075606920.036225385

Mean Left Amygdala-medial Prefrontal Cortex BOLD Connectivity During Implicit Emotion Face Processing Task Over Time

"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks

,
Interventionarbitrary units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.02130.00111
Hormone Sensitive Women (HS+)0.0247-0.0192

Mean Reactive Aggression During Hormone Addback Over Time

"This outcome measure determines the extent to which HS+ is characterized by reactive aggression during hormone addback relative to baseline in the target population. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to accrue money or press another button to subtract money from a (fictional) partner at no direct gain to themselves. Frustration is induced by periodic subtractions of their own money, which is attributed to the partner." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionNumber of subtraction responses (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)129.2054.90
Hormone Sensitive Women (HS+)103.0834.62

Mean Right Amygdala-medial Prefrontal Cortex BOLD Connectivity During Implicit Emotion Face Processing Task Over Time

"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) Blood-oxygen-level-dependent (BOLD) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks

,
Interventionarbitrary units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.05330.00804
Hormone Sensitive Women (HS+)0.0174-0.0114

Mean Threat Processing Bias During Visual Dot-probe Paradigm Over Time

"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS- by examining threat attention bias assessed during the visual dot-probe paradigm.~The Visual Dot-Probe Paradigm asks participants to detect a target stimulus that is embedded in a matrix of distracting stimuli (e.g., a target stimulus, an angry face, might be embedded in a matrix of neutral distractor faces). Attention biases are inferred from faster response times to detect a threatening stimulus in a matrix of neutral stimuli relative to response time to detect neutral stimuli in neutral matrices. Thus, positive times reflect attention bias toward threat, whereas negative times reflect attention bias away from threat." (NCT04051320)
Timeframe: up to 6 weeks

,
Interventionattention bias in milliseconds (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)36.92-42.35
Hormone Sensitive Women (HS+)-0.57-9.04

Reviews

1 review available for creatine and Menopause

ArticleYear
Creatine Supplementation in Women's Health: A Lifespan Perspective.
    Nutrients, 2021, Mar-08, Volume: 13, Issue:3

    Topics: Adult; Affect; Aged; Body Composition; Brain; Creatine; Dietary Supplements; Exercise; Female; Human

2021

Trials

1 trial available for creatine and Menopause

ArticleYear
Bone loss during oestriol therapy in postmenopausal women.
    Maturitas, 1979, Volume: 1, Issue:4

    Topics: Adult; Alkaline Phosphatase; Bone and Bones; Calcium; Clinical Trials as Topic; Creatine; Double-Bli

1979

Other Studies

6 other studies available for creatine and Menopause

ArticleYear
[Effects of estrogen replacement therapy on cognitive function of ovariectomized rats].
    Zhonghua fu chan ke za zhi, 2014, Volume: 49, Issue:1

    Topics: Animals; Aspartic Acid; Cognition; Creatine; Disease Models, Animal; Estradiol; Estrogen Replacement

2014
DAY-TO-DAY VARIATION IN LH EXCRETION IN CARCINOMA OF THE ENDOMETRIUM AND NORMAL MENOPAUSE.
    American journal of obstetrics and gynecology, 1964, Mar-15, Volume: 88

    Topics: Creatine; Creatinine; Endometrium; Female; Gonadotropins; Gonadotropins, Pituitary; Humans; Luteiniz

1964
THE KIDNEY FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN RELATION TO THE COMMENCEMENT OF THE DISEASE. VI.
    Acta rheumatologica Scandinavica, 1964, Volume: 10

    Topics: Adolescent; Arthritis; Arthritis, Rheumatoid; Creatine; Creatinine; Female; Geriatrics; Humans; Kidn

1964
HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL.
    Science (New York, N.Y.), 1964, Aug-14, Volume: 145, Issue:3633

    Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androsterone; Breast Neoplasms; Creatine; Creatinine

1964
Effects of estrogen on daylong circulating calcium, phosphorus, 1,25-dihydroxyvitamin D, and parathyroid hormone in postmenopausal women.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1990, Volume: 5, Issue:8

    Topics: Aged; Calcitriol; Calcium; Circadian Rhythm; Creatine; Cyclic AMP; Estrogens; Female; Humans; Hydrox

1990
Biologic effects of transdermal estradiol.
    The New England journal of medicine, 1986, Jun-19, Volume: 314, Issue:25

    Topics: Administration, Oral; Administration, Topical; Blood Coagulation Factors; Calcium; Carrier Proteins;

1986